Vial Logo

Updates

Search
All Resources
Press Releases
Videos

Dr. Jason Fung, MD, believes that targeting fat distribution via INHBE is beneficial for overall metabolic health

Dr. Lee Kaplan MD, Director of Dartmouth Health’s Weight and Wellness Center, suggests new MoAs to tackle the GI intolerance of GLP-1s and highlights Vial’s INHBE siRNA program as a promising target to compliment and potentially enhance current treatments.

The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy

Read Article

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, emphasizes how Vial’s INHBE siRNA directly impacts the function of adipose tissue to better address cellular hypertrophy and inflammation.

Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE siRNA as a promising target to drive quality fat loss.

Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies.

Dr. Lee Kaplan, Director at Dartmouth Health’s Weight and Wellness Center, points to the myostatin/activin pathway as a promising target.

Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research on the next breakthroughs in obesity treatment.

Vial’s INHBE siRNA is designed to block Activin E signaling and increase lipolysis for fat-selective weight loss selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Load More

Dr. Jason Fung, MD, believes that targeting fat distribution via INHBE is beneficial for overall metabolic health

Dr. Lee Kaplan MD, Director of Dartmouth Health’s Weight and Wellness Center, suggests new MoAs to tackle the GI intolerance of GLP-1s and highlights Vial’s INHBE siRNA program as a promising target to compliment and potentially enhance current treatments.

The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy

Read Article

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, emphasizes how Vial’s INHBE siRNA directly impacts the function of adipose tissue to better address cellular hypertrophy and inflammation.

Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE siRNA as a promising target to drive quality fat loss.

Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies.

Dr. Lee Kaplan, Director at Dartmouth Health’s Weight and Wellness Center, points to the myostatin/activin pathway as a promising target.

Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research on the next breakthroughs in obesity treatment.

Vial’s INHBE siRNA is designed to block Activin E signaling and increase lipolysis for fat-selective weight loss selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Contact

Information

E: contact@vial.com
S: Linkedin, X

Join our mail list

"*" indicates required fields

Get in touch!

Compose the future with us

"*" indicates required fields

This field is for validation purposes and should be left unchanged.